PARP vs. CDK4/6 Inhibitors: Which Comes First in HR+ BRCA+ Disease?

When both PARP and CDK4/6 inhibitors are options, which should be used first? Drs. Iyengar and Robson discuss adjuvant sequencing strategies in high-risk hormone receptor–positive BRCA-mutated breast cancer — and how trial criteria inform today’s decisions.